Ranked #3,650 of 8,699 institutional investors
Jones Hill Capital LP
New York, NY
$495M
US stock portfolio at live prices · today −$4.7M (−0.94%)
Live prices, last trade 11:28 AM ET
- Value at quarter end (Q3 2026)
- $589M
- Change from Q2 2026
- +$118.8M (+25.26%)
- Positions
- 30 · 17 new, 14 sold out
- Filed
- Nov 13, 2026
Not counted in the ranking: none$57.4M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesBMRN 14.4%BCRX 10.5%TVTX 9.34%SUPN 8.97%CELC 4.25%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical Inc. | 1,171,859 | $71.5M | 14.4% | Reduced −18% |
| BCRX BioCryst Pharmaceuticals, Inc. | 7,083,300 | $51.9M | 10.5% | New |
| TVTX Travere Therapeutics, Inc. | 959,634 | $46.3M | 9.34% | New |
| SUPN Supernus, Inc. | 1,526,685 | $44.4M | 8.97% | New |
| CELC Celcuity Inc. | 382,901 | $21.0M | 4.25% | New |
| TRVI Trevi Therapeutics, Inc. | 1,447,156 | $19.3M | 3.91% | Added +8% |
| NUVB Nuvation Bio Inc. | 4,486,986 | $17.1M | 3.45% | New |
| VERA Vera Therapeutics, Inc. | 652,218 | $16.8M | 3.40% | New |
| IONS Ionis Pharmaceuticals, Inc. | 599,826 | $16.5M | 3.33% | New |
| INSM Insmed Incorporated | 106,528 | $15.5M | 3.13% | Reduced −13% |
| RLMD Relmada Therapeutics, Inc. | 5,237,628 | $15.1M | 3.05% | Added +43% |
| NBIX Neurocrine Biosciences, Inc. | 83,426 | $12.8M | 2.59% | New |
| IMCR Immunocore Holdings plc | 384,278 | $10.2M | 2.07% | Reduced −25% |
| ABVX ABIVAX Société Anonyme | 142,558 | $9.8M | 1.99% | New |
| BCAX Bicara Therapeutics Inc. | 1,064,233 | $9.5M | 1.93% | Added +19% |
| ACRS Aclaris Therapeutics, Inc. | 2,504,651 | $8.7M | 1.76% | Added +42% |
| ERAS Erasca, Inc. | 610,118 | $8.6M | 1.73% | New |
| CAPR Capricor Therapeutics, Inc. | 892,532 | $7.0M | 1.42% | Added +112% |
| DNTH Dianthus Therapeutics, Inc. | 80,017 | $6.7M | 1.35% | Added +40% |
| NGNE Neurogene Inc. | 217,700 | $4.9M | 1.00% | New |
| DYN Dyne Therapeutics, Inc. | 300,900 | $4.8M | 0.97% | New |
| SGMT Sagimet Biosciences Inc. | 502,587 | $4.6M | 0.92% | New |
| AVLN Avalyn Pharma Inc. | 126,744 | $3.5M | 0.71% | New |
| ATTO Attovia Therapeutics, Inc. | 182,295 | $2.8M | 0.56% | New |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | 886,428 | $2.0M | 0.40% | Added +36% |
| LXEO Lexeo Therapeutics, Inc. | 593,737 | $1.9M | 0.38% | New |
| OLMA Olema Oncology, Inc. | 206,397 | $1.5M | 0.30% | Reduced −64% |
| TNXP Tonix Pharmaceuticals Holding Corp. | 563,739 | $1.4M | 0.28% | Reduced −10% |
| PHAT Phathom Pharmaceuticals, Inc. | 276,830 | $1.3M | 0.27% | Added +71% |
| TENX Tenax Therapeutics, Inc. | 122,169 | $158K | <0.1% | New |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| GILD Gilead Sciences, Inc. | 343,043 | $58.0M |
| ARQT Arcutis Biotherapeutics, Inc. | 1,089,701 | $29.2M |
| AMLX Amylyx Pharmaceuticals, Inc. | 894,058 | $23.2M |
| MDGL Madrigal Pharmaceuticals, Inc. | 52,545 | $20.5M |
| ANIP ANI Pharmaceuticals, Inc. | 233,808 | $16.0M |
| XENE Xenon Pharmaceuticals Inc. | 367,900 | $13.7M |
| VRTX Vertex Pharmaceuticals Incorporated | 11,123 | $5.8M |
| VIR Vir Biotechnology, Inc. | 659,213 | $5.7M |
| ORIC ORIC Pharmaceuticals, Inc. | 747,313 | $5.7M |
| IMUX Immunic, Inc. | 539,814 | $3.9M |
| SNDX Syndax Pharmaceuticals, Inc. | 340,000 | $3.0M |
| ELVN Enliven Therapeutics, Inc. | 49,850 | $2.3M |
| GPCR Structure Therapeutics Inc. | 40,567 | $672K |
| QUIT Achieve Life Sciences, Inc. | 26,760 | $153K |